-
Gao Yaxiang, general manager of Zhejiang Xinlei Compressor unveiled at the 2021 compressed air dual-carbon energy-saving forum
Time of Update: 2021-11-04
To this end, the Shanghai Air Standard Compressor Technology Testing Center and the Shanghai International Biological Fermentation Exhibition Organizing Committee jointly organized this summit forum, and specially invited senior experts from related industries for exchanges and discussions .
-
The development of the domestic pharmaceutical industry continues to improve, and a large number of talents from multinational pharmaceutical companies are turning to local companies
Time of Update: 2021-11-04
Eid, an expert in the medical field, officially announced that he would join Hengrui Medicine in October as executive vice president, chief medical officer and head of global drug development .
-
Three quarterly report disclosures are gradually reaching a climax: the performance of pharmaceutical companies is mixed
Time of Update: 2021-11-04
According to the 2021 third quarter report of Zhenghai Biological, the company's main operating income was 301 million yuan, a year-on-year increase of 39.
-
Sansheng Guojian SSGJ-706 was approved by the FDA to enter Phase I-II clinical trials
Time of Update: 2021-11-04
On October 18th, Sansheng Guojian issued an announcement stating that the company's SSGJ-706 treatment of advanced solid tumors, relapsed or refractory lymphomas has been approved by the US FDA to ent
-
The Fortune Global 500 Summit was held in Hangzhou, Guangyao Li Chuyuan: Fulfilling the Mission of Traditional Chinese Medicine for Human Health
Time of Update: 2021-11-04
Li Chuyuan introduced the practices and responsibilities of Guangzhou Pharmaceutical Group in fighting the epidemic, and focused on the important role played by Chinese medicine in global health .
-
SHPL-49 injection, a new class 1 chemical drug of Shanghai Hutchison Pharmaceuticals, obtained NMPA and FDA clinical trial approval
Time of Update: 2021-11-04
The SHPL-49 injection was approved for clinical trials in China and the United States, marking the staged success of the collaborative innovation and achievement transformation of Shanghai University of Traditional Chinese Medicine and Shanghai Hutchison Pharmaceuticals .
-
Tasly's subsidiary bezafibrate sustained-release tablets and temozolomide for injection obtained drug registration certificates
Time of Update: 2021-11-04
On October 21, Tasly issued an announcement stating that its subsidiaries, bezafibrate sustained-release tablets and temozolomide for injection, have obtained drug registration certificates .
Sustained-release bezafibrate tablets are used to treat adult hypertriglyceridemia and mixed hyperlipidemia .
-
With the general rise in the performance of the third quarterly reports of medical companies, they are still facing severe performance tests
Time of Update: 2021-11-04
613 billion yuan and net profit attributable to shareholders of listed companies of 2.
It is worth noting that since its listing in October 2018, Mindray Medical's single-quarter net profit growth rate has continued to remain above 20% .
-
Target EGFR×HER3!
Time of Update: 2021-11-04
ArticleMedicine GuanlanAccording to information published on the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China, the BL-B01D1 for injection declared by Bailey Pharmaceutical has obtained a clinical implied license and is intended to be developed for the treatment of locally advanced or metastatic epithelial tumors .
-
The tuberculosis war never stopped: an overview of multidrug-resistant tuberculosis drugs
Time of Update: 2021-11-04
On November 23, 2016, the drug was approved by the China National Medical Products Administration NMPA (trade name Snair) for the treatment of multi-drug-resistant tuberculosis .
-
Guangxi vigorously promotes the development of the traditional Chinese medicine industry, and the number of reimbursable pieces of traditional Chinese medicine has increased
Time of Update: 2021-11-04
Some time ago, the Guangxi Medical Insurance Bureau and the Department of Human Resources and Social Security jointly issued the "Notice on Further Strengthening the Management of the Catalogue of Traditional Chinese Medicine and Ethnic Medicine Decoction Pieces in Guangxi Basic Medical Insurance, Work Injury Insurance and Maternity Insurance .
-
You can't play with the full variety of Chinese herbal medicine
Time of Update: 2021-11-04
Traditional Chinese medicine is also a typical non-standard product, which can be large or small, long or segmented, round or flat, or old and new; how can you effectively control quality at low cost?This is a naked challenge to the scientific management of industrialization!
-
Analysis of the layout of Chinese innovative drugs at home and abroad: Do not all innovative drugs have a future?
Time of Update: 2021-11-04
Analysis of the overall situation of China's pharmaceutical industryOn October 8, 2021, Evive Biotech, a holding subsidiary of Evive Biotech, announced that the European Medicines Agency (EMA) has officially accepted Evive Ryzneuta™ for the treatment of chemotherapy-induced neutropenia (CIN).
-
Shandong and Shanxi alliance cut drug prices: 50 drugs fell by more than 92%
Time of Update: 2021-11-04
On October 19, the results of the second batch of (Lu-Jin Alliance) drug centralized procurement in Shandong Province were announced .
This time the Lu-Jin alliance gathered, patients in Shandong and Shanxi provinces will soon use the reduced-price medicines .
-
A quick look at the news about foreign "medicine" this month
Time of Update: 2021-11-04
A quick overview of key foreign drug news this month: Roche T drug was approved to treat early lung cancer; FDA approved Merck K drug combined with chemotherapy for first-line treatment of cervical cancer; AstraZeneca Imfinzi combined with tremelimumab to treat liver cancer phase 3 clinical end; Eli Lilly Verzenio was awarded FDA approved the treatment of early breast cancer .
-
Beihai Kangcheng's clinical trial application for the treatment of Gaucher's disease CAN103 new drug approved in China
Time of Update: 2021-11-04
(hereinafter referred to as "Beihai Kangcheng") is a leading rare disease biopharmaceutical company based in China and has been committed to For the research, development and commercialization of innovative therapies .
-
Hebo Medicine Bartolizumab completes the first patient's administration for Phase II trial of thyroid ophthalmopathy
Time of Update: 2021-11-04
HK) recently announced its fully human anti-FcRn antibody Bartoli The phase II clinical trial of monoclonal antibody (HBM9161) for thyroid eye disease has completed the first administration of the first subject .
-
Jiangsu's biopharmaceutical industry continues to develop rapidly and is opening up a "blue ocean"
Time of Update: 2021-11-04
For example, the "Opinions" put forward 18 measures in five aspects: stimulating industrial innovation vitality, accelerating listing review and approval, promoting the quality improvement of the pharmaceutical industry, strengthening the construction of technical support capabilities, and improving the working mechanism of service development.
-
Osaikon's subsidiary zoledronic acid concentrated solution for injection obtained the notification of acceptance of the listing application
Time of Update: 2021-11-04
On October 21, Osaikang issued an announcement stating that its wholly-owned subsidiary, Jiangsu Osaikang, had recently received the "Notice of Acceptance" for the marketing application for concentrated zoledronic acid solution for injection issued by the National Medical Products Administration .
-
Development Pharmaceuticals PD-L1/TGF-β dual target antibody obtained clinical trial license in China
Time of Update: 2021-11-04
HK, hereinafter referred to as "Kaifeng Pharmaceutical") is pleased to announce that PD-L1/ The TGF-β dual target antibody (GT90008) has been approved by the National Medical Products Administration (NMPA) of China today to carry out clinical trials for the treatment of advanced solid tumors .
